BioInvent International AB (publ) (STO:BINV)

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Develops Antibody-Based Drugs	226.50M	44.69M	71.46M	326.13M	19.38M
Total	226.50M	44.69M	71.46M	326.13M	19.38M

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Sweden	13.72M	3.89M	18.26M	25.63M	13.52M
Europe	1.24M	2.93M	2.95M	27.10M	4.21M
USA	210.95M	36.82M	47.39M	273.39M	1.66M
Other Countries	582.00K	1.05M	2.85M	-	-
Total	226.50M	44.69M	71.46M	326.13M	19.38M

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error